The approach to clinical trials needs to be different in rare cancers where large randomised trials are impractical, says Professor Ian Olver in an editorial published today in the Medical Journal of Australia. He wrote that ovarian cancer was a good example of how approaches to rare cancer treatment needed to evolve. The heterogeneity of ovarian ...
Approach to rare cancers need to change: Olver
18 Nov 2015